Literature DB >> 22897466

Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.

L S Briongos-Figuero1, T Gómez-Traveso, P Bachiller-Luque, M Domínguez-Gil González, A Gómez-Nieto, T Palacios-Martín, M González-Sagrado, A Dueñas-Laita, J L Pérez-Castrillón.   

Abstract

AIM: Urinary tract infection (UTI) caused by resistant bacteria is becoming more prevalent. We investigate characteristics and associated risk factors for UTIs resulting from extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.
METHODS: Retrospective study of urinary tract isolates of ESBL-producing enterobacteria in adults (2009 and 2010). We included 400 patients and 103 controls (UTI caused by non-ESBL Escherichia coli). Clinical and demographic information was obtained from medical records. Comorbidity was evaluated using Charlson Index (CI). Strains were identified using VITEK 2 system.
RESULTS: A total of 400 isolates were obtained (93%E. coli and 7%Klebsiella spp). In 2009, 6% of cultures were ESBL-producing E. coli and 7% in 2010. 37% of patients were men and 81% were aged ≥60years. CI was 2.3±1.8 (high comorbidity: 42.8%). 41.5% of strains were susceptible to amoxicillin-clavulanate, 85.8% to fosfomycin and 15.5% to ciprofloxacin. The total number of ESBL E. coli positive urine cultures during hospital admission was 97 and, compared with 103 controls, risk factors for UTI caused by ESBL- E. coli strains in hospitalised patients were nursing home residence (p<0.001), diabetes (p=0.032), recurrent UTI (p=0.032) and high comorbidity (p=0.002). In addition, these infections were associated with more symptoms (p<0.001) and longer admission (p=0.004).
CONCLUSIONS: Urinary tract infection caused by ESBL are a serious problem and identifying risk factors facilitates early detection and improved prognosis. Male sex, hospitalisation, institutionalisation, diabetes, recurrent UTI and comorbidity were risk factors and were associated with more symptoms and longer hospital stay.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22897466     DOI: 10.1111/j.1742-1241.2012.02991.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  40 in total

1.  Switching from CLSI to EUCAST XL susceptibility breakpoint: its implication in urinary tract infection in men.

Authors:  Amaia Aguirre-Quiñonero; M C Lecaroz Agara; A Canut Blasco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-23       Impact factor: 3.267

Review 2.  A scoping review of important urinary catheter induced complications.

Authors:  K H Dellimore; A R Helyer; S E Franklin
Journal:  J Mater Sci Mater Med       Date:  2013-05-10       Impact factor: 3.896

3.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.

Authors:  Liam Toner; Nathan Papa; Sani H Aliyu; Harveer Dev; Nathan Lawrentschuk; Samih Al-Hayek
Journal:  World J Urol       Date:  2015-10-28       Impact factor: 4.226

Review 4.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

5.  Bacterial drug-resistance patterns and genetic diversity of bacteria-associated bacteriuria in diabetic patients in Ghana.

Authors:  Akua Obeng Forson; Dickson Agyei Menkah; Marjorie Ntiwaa Quarchie; Shittu Bunkunmi Dhikrullahi; Michael Olu-Taiwo; Francis Samuel Codjoe
Journal:  IJID Reg       Date:  2021-10-28

6.  Clinical and Molecular Characterization of Community-Onset Urinary Tract Infections Due to Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae.

Authors:  Judith A Anesi; Ebbing Lautenbach; Irving Nachamkin; Charles Garrigan; Warren B Bilker; Mary Wheeler; Pam Tolomeo; Jennifer H Han
Journal:  Infect Control Hosp Epidemiol       Date:  2016-09-28       Impact factor: 3.254

7.  Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.

Authors:  Helio S Sader; Mariana Castanheira; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study.

Authors:  Basima A Almomani; Wail A Hayajneh; Abeer M Ayoub; Mera A Ababneh; Miral A Al Momani
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

9.  Urosepsis Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: A Retrospective, Single-Centre Review of Risk Factors and Clinical Outcomes.

Authors:  Yi-Wenn Yvonne Huang; Alison Alleyne; Vivian Leung; Michael Chapman
Journal:  Can J Hosp Pharm       Date:  2018-04-30

10.  Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Irene Sandven; Cathrine Brunborg; Pål A Jenum
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.